Lovell, Daniel J.
Dare, Jason A.
Francis-Sedlak, Megan
Ball, Julie
LaMoreaux, Brian D.
Von Scheven, Emily
Reinhardt, Adam
Jerath, Rita
Alpan, Oral
Gupta, Ramesh
Goldsmith, Donald
Zeft, Andrew
Naddaf, Henry
Gottlieb, Beth
Jung, Lawrence
Holt, Robert J. http://orcid.org/0000-0001-7526-2273
Funding for this research was provided by:
Horizon Pharma USA, Inc. (None)
Article History
Received: 29 May 2018
Accepted: 14 June 2018
First Online: 26 June 2018
Ethics approval and consent to participate
: An Institutional Review Board (IRB)/Ethics Committee (EC) from each clinical study site approved the final study protocol, and the final version of the informed consent form and assent form and any other written information and/or materials provided to the patients before any patients were entered in the study. Before being implemented, protocol amendments were reviewed and approved by the IRBs.
: Not applicable.
: D.J.L. receives grant / research support from the National Institutes of Health, NIAMS; Cincinnati Children’s Hospital Medical Center receives funds for DJL consulting from AstraZeneca, Bristol-Myers Squibb, AbbVie, Pfizer, Roche, Novartis, UBC, Forest Research Institute, Horizon, Johnson & Johnson, Biogen, Takeda, Genentech, GlaxoSmithKline, Boehringer Ingelheim, Celgene, and Janssen for consulting; He is on the speaker bureaus of Genentech and Bristol Meyers Squibb. J.A.D. has received research support from AbbVie, AstraZeneca, Bristol-Myers Squibb, Horizon Pharma, Medac, Pfizer, Roche and UCB. D.G. is on Novartis speaker bureau. L.J. has received research support from Abbvie, GSk, Hoffman-Laroche, Pfizer and UCB. A.Z. has stock ownership in Merck and OPKO. J.B., B.D.L., M. F. and R.J. H. are employees of, and have stock in, Horizon Pharma USA, Inc.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.